Sie sind bereits eingeloggt. Klicken Sie auf 2. tolino select Abo, um fortzufahren.
Bitte loggen Sie sich zunächst in Ihr Kundenkonto ein oder registrieren Sie sich bei bücher.de, um das eBook-Abo tolino select nutzen zu können.
This volume provides a concise yet comprehensive overview of minimal residual disease (MRD) testing. The text reviews the history of MRD testing, MRD testing for acute lymphoblastic leukemia/lymphoma, molecular diagnostics for MRD analysis in hematopoietic malignancies, the use of "difference from normal" flow cytometry in monitoring AML response, ML-DS for measurable residual disease detection, and advancements in next generation sequencing for detecting MRD. Written by experts in the field, Minimal Residual Disease Testing: Current Innovations and Future Directions is a valuable resource…mehr
This volume provides a concise yet comprehensive overview of minimal residual disease (MRD) testing. The text reviews the history of MRD testing, MRD testing for acute lymphoblastic leukemia/lymphoma, molecular diagnostics for MRD analysis in hematopoietic malignancies, the use of "difference from normal" flow cytometry in monitoring AML response, ML-DS for measurable residual disease detection, and advancements in next generation sequencing for detecting MRD.
Written by experts in the field, Minimal Residual Disease Testing: Current Innovations and Future Directions is a valuable resource for hematologists, oncologists, pathologists, and radiologists on the variety of technologies available to detect MRD and how best to integrate these platforms into clinical practice.
Todd E. Druley, MD, PhD Associate Professor of Pediatrics, Genetics and Developmental Biology Director, Fellowship Program in Pediatric Hematology and Oncology Director, Pediatric Cancer Predisposition Program Washington University in St. Louis Department of Pediatrics Division of Hematology and Oncology Center for Genome Sciences and Systems Biology St. Louis, MO USA
Inhaltsangabe
Introduction.- Minimal Residual Disease Testing in Acute Lymphoblastic Leukemia/Lymphoma.- Molecular Diagnostics for Minimal Residual Disease Analysis in Hematopoietic Malignancies.- Monitoring AML Response Using “Difference From Normal” Flow Cytometry.- ML-DS: A Unique Condition for Measurable Residual Disease Detection.- Advancements in Next Generation Sequencing for Detecting Minimal Residual Disease.
Introduction.- Minimal Residual Disease Testing in Acute Lymphoblastic Leukemia/Lymphoma.- Molecular Diagnostics for Minimal Residual Disease Analysis in Hematopoietic Malignancies.- Monitoring AML Response Using "Difference From Normal" Flow Cytometry.- ML-DS: A Unique Condition for Measurable Residual Disease Detection.- Advancements in Next Generation Sequencing for Detecting Minimal Residual Disease.
Introduction.- Minimal Residual Disease Testing in Acute Lymphoblastic Leukemia/Lymphoma.- Molecular Diagnostics for Minimal Residual Disease Analysis in Hematopoietic Malignancies.- Monitoring AML Response Using “Difference From Normal” Flow Cytometry.- ML-DS: A Unique Condition for Measurable Residual Disease Detection.- Advancements in Next Generation Sequencing for Detecting Minimal Residual Disease.
Introduction.- Minimal Residual Disease Testing in Acute Lymphoblastic Leukemia/Lymphoma.- Molecular Diagnostics for Minimal Residual Disease Analysis in Hematopoietic Malignancies.- Monitoring AML Response Using "Difference From Normal" Flow Cytometry.- ML-DS: A Unique Condition for Measurable Residual Disease Detection.- Advancements in Next Generation Sequencing for Detecting Minimal Residual Disease.
Es gelten unsere Allgemeinen Geschäftsbedingungen: www.buecher.de/agb
Impressum
www.buecher.de ist ein Shop der buecher.de GmbH & Co. KG Bürgermeister-Wegele-Str. 12, 86167 Augsburg Amtsgericht Augsburg HRA 13309